Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma

Kanda,Mitsuro; Sugimoto,Hiroyuki; Nomoto,Shuji; Oya,Hisaharu; Shimizu,Dai; Takami,Hideki; Hashimoto,Ryoji; Sonohara,Fuminori; Okamura,Yukiyasu; Yamada,Suguru; Fujii,Tsutomu; Nakayama,Goro; Koike,Masahiko; Fujiwara,Michitaka; Kodera,Yasuhiro

doi:10.3892/ijo.2014.2637

Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma

Authors:
- Mitsuro Kanda
- Hiroyuki Sugimoto
- Shuji Nomoto
- Hisaharu Oya
- Dai Shimizu
- Hideki Takami
- Ryoji Hashimoto
- Fuminori Sonohara
- Yukiyasu Okamura
- Suguru Yamada
- Tsutomu Fujii
- Goro Nakayama
- Masahiko Koike
- Michitaka Fujiwara
- Yasuhiro Kodera
View Affiliations

Affiliations: Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
Published online on: September 3, 2014 https://doi.org/10.3892/ijo.2014.2637
Pages: 2005-2012

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of novel genetic and epigenetic alterations is required for optimal stratification of patients with hepatocellular carcinoma (HCC) at risk for recurrence and adverse prognosis. Coenzyme Q10 (CoQ10), which mediates apoptosis, is synthesized by prenyl diphosphate synthase subunit 2 (PDSS2). In the present study we evaluated the clinical significance and regulatory mechanisms of PDSS2 expression in HCC. PDSS2 expression levels and those of genes encoding potentially interacting proteins as well as the methylation status of the PDSS2 promoter region were analyzed in HCC cell lines. PDSS2 mRNA levels in 151 pairs of resected specimens were determined to evaluate the association of PDSS2 expression and clinicopathological factors. The expression and distribution of PDSS2 were determined using immunohistochemistry. PDSS2 mRNA expression was decreased in six of nine HCC cell lines and significantly correlated with those of hepatocyte nuclear factor 4α. PDSS2 transcription in HCC cells with decreased PDSS2 expression accompanying hypermethylation was reactivated after treating these cells with a methylation inhibitor. Mean expression levels of PDSS2 mRNA relative to that of uninvolved liver diminished gradually in the order of chronic hepatitis to cirrhosis, and each was significantly higher than those of HCCs. PDSS2 and PDSS2 mRNA levels were consistent. Decreased PDSS2 mRNA levels were detected in HCC tissues of 56 patients, correlated with shorter disease-specific survival, and was identified as an independent prognostic factor. PDSS2 is a putative tumor suppressor, and promoter hypermethylation is a key regulatory mechanism in HCC. Decreased levels of PDSS2 mRNA expression may represent a novel biomarker of HCC.

View Figures

View References

1	Minguez B and Lachenmayer A: Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers. 31:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kanda M, Nomoto S, Oya H, et al: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 44:44–52. 2014.PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
4	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
5	Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138. 2013.PubMed/NCBI
6	El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 127:S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kanda M, Nomoto S, Nishikawa Y, et al: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol. 98:190–196. 2008. View Article : Google Scholar : PubMed/NCBI
8	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
9	Kanda M, Nomoto S, Okamura Y, et al: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
10	El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
11	Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007. View Article : Google Scholar : PubMed/NCBI
12	Miki D, Ochi H, Hayes CN, Aikata H and Chayama K: Hepatocellular carcinoma: towards personalized medicine. Cancer Sci. 103:846–850. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kanda M, Nomoto S, Okamura Y, et al: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 35:477–483. 2009.
14	Herath NI, Leggett BA and MacDonald GA: Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol. 21:15–21. 2006. View Article : Google Scholar : PubMed/NCBI
15	Saiki R, Nagata A, Kainou T, Matsuda H and Kawamukai M: Characterization of solanesyl and decaprenyl diphosphate synthases in mice and humans. FEBS J. 272:5606–5622. 2005. View Article : Google Scholar : PubMed/NCBI
16	Fung JM, Smith R, Brown MA, et al: Identification and characterization of a novel melanoma tumor suppressor gene on human chromosome 6q21. Clin Cancer Res. 15:797–803. 2009. View Article : Google Scholar : PubMed/NCBI
17	Turunen M, Olsson J and Dallner G: Metabolism and function of coenzyme Q. Biochim Biophys Acta. 1660:171–199. 2004. View Article : Google Scholar : PubMed/NCBI
18	Quinzii CM, DiMauro S and Hirano M: Human coenzyme Q10 deficiency. Neurochem Res. 32:723–727. 2007. View Article : Google Scholar
19	DiMauro S, Quinzii CM and Hirano M: Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest. 117:587–589. 2007. View Article : Google Scholar : PubMed/NCBI
20	Chen P, Yu J, Knecht J and Chen Q: Decrease of PDSS2 expression, a novel tumor suppressor, in non-small cell lung cancer. Cancer Epidemiol. 37:166–171. 2013. View Article : Google Scholar : PubMed/NCBI
21	Takami H, Kanda M, Oya H, et al: Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol. 108:557–562. 2013. View Article : Google Scholar : PubMed/NCBI
22	Sobin LH, Gospodarowicz MK and Wittekind Ch: International Union Against Cancer: TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; New York: 2009
23	Oya H, Kanda M, Takami H, et al: Overexpression of melanomaassociated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus. Oct 2–2013.(Epub ahead of print). View Article : Google Scholar
24	Kanda M, Shimizu D, Nomoto S, et al: Prognostic impact of expression and methylation status of DENN/MADD domaincontaining protein 2D in gastric cancer. Gastric Cancer. Apr 3–2014.(Epub ahead of print).
25	Shimizu D, Kanda M, Nomoto S, et al: Identification of intragenic methylation in the TU SC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep. 31:1305–1313. 2014.PubMed/NCBI
26	Takai D and Jones PA: The CpG island searcher: a new WWW resource. In Silico Biol. 3:235–240. 2003.PubMed/NCBI
27	Hibino S, Kanda M, Oya H, et al: Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep. 31:693–700. 2014.PubMed/NCBI
28	Saandi T, Baraille F, Derbal-Wolfrom L, et al: Regulation of the tumor suppressor homeogene Cdx2 by HNF4alpha in intestinal cancer. Oncogene. 32:3782–3788. 2013. View Article : Google Scholar : PubMed/NCBI
29	Kanda M, Shimizu D, Nomoto S, et al: Clinical significance of expression and epigenetic profiling of TU SC1 in gastric cancer. J Surg Oncol. 110:136–144. 2014. View Article : Google Scholar : PubMed/NCBI
30	Nagai H, Pineau P, Tiollais P, Buendia MA and Dejean A: Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene. 14:2927–2933. 1997. View Article : Google Scholar : PubMed/NCBI
31	Li SP, Wang HY, Li JQ, et al: Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol. 34:840–849. 2001. View Article : Google Scholar : PubMed/NCBI
32	Walesky C, Edwards G, Borude P, et al: Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 57:2480–2490. 2013. View Article : Google Scholar
33	Ehehalt F, Rummele P, Kersting S, et al: Hepatocyte nuclear factor (HNF) 4alpha expression distinguishes ampullary cancer subtypes and prognosis after resection. Ann Surg. 254:302–310. 2011. View Article : Google Scholar